Edge Medical Posts 1H26 Revenue Surge of 113.8%, Net Loss Narrows 78.4%

Bulletin Express09-23

Shenzhen Edge Medical Co., Ltd. (EDGE MEDICAL-B) released its unaudited interim results for the six months ended 30 June 2026.

Financial Performance • Revenue jumped 113.8% year on year to RMB 319.32 million, driven by rapid uptake of surgical robot systems across domestic and overseas markets. • Gross profit doubled to RMB 204.63 million; gross margin improved to 64.1% from 62.8% a year earlier, reflecting stronger cost controls and scale benefits. • Net loss narrowed sharply by 78.4% to RMB 19.25 million; basic and diluted loss per share decreased to RMB 0.05 from RMB 0.25. • R&D expenses contracted 44.2% to RMB 53.84 million; selling and marketing expenses rose 49.1% to RMB 87.46 million on intensified overseas promotion. • Cash and cash equivalents expanded to RMB 1.26 billion, bolstered by HK$ 1.29 billion in net proceeds from the January 2026 Hong Kong IPO and over-allotment option.

Operational Highlights • 58 surgical robots were installed or delivered during the period (9 in China, 49 overseas), lifting cumulative global installations to 158. • Overseas revenue contributed 69.8% of total revenue, underpinned by deployments in Brazil, Poland, Italy and Hungary. • The company’s Edge Multi-Port and Single-Port Endoscopic Surgical Robots have been approved or registered in 63 countries and regions; cumulative robot-assisted procedures in China exceeded 21,600 by 30 June 2026.

Capital Management • Gross IPO proceeds totaled approximately RMB 1.24 billion; share capital rose to 391.88 million shares. • During June 2026, the company repurchased 1.82 million H shares for HK$ 68.00 million, which are held as treasury shares. • Gearing ratio declined to 7.0% (31 December 2025: 13.5%) and current ratio strengthened to 19.5 (31 December 2025: 8.1).

Outlook Management plans to deepen domestic hospital penetration, accelerate overseas commercialization, advance R&D—particularly in AI-enabled surgical robotics—and maintain disciplined cost control to pursue sustainable profitability.

The Board did not declare an interim dividend for the period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment